title: The latest drug therapies for treating IBS.  Longtime sufferers of irritable bowel syndrome have new options for relief.
mesh_terms: D002908:Chronic Disease; D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D005765:Gastrointestinal Agents; D007093:Imidazoles; D010455:Peptides; D012294:Rifamycins; C583636:eluxadoline; D010649:Phenylalanine; D000078262:Rifaximin; C523483:linaclotide